

Top 20: CHINA - Growth Despite Crackdowns

04 July 2014 | Analysis | By BioSpectrum Bureau





China has cracked down on high prices and corruption in the healthcare sector. Nonetheless, the revenue growth of publicly listed companies grew by nearly 22 percent.

Today, China accounts for nearly 50 percent share of the total market.

China's leading company Sinopharm alone is the size of combined revenue of India's publicly listed bioscience companies.

The top three companies contributed almost 62 percent share of the total revenue of China bioscience market.

China has almost eight companies which have over \$1 billion in revenue.

China takes firm steps against drug makers who were caught bribing doctors and other health authorities to the extent of blacklisting them in the country.

China confiscated \$362 million worth of drugs and raw materials in an action against drug counterfeiters selling over the

Internet.

China is set to build its first national biobank developed in partnership by with BGI-Shenzhen and China National Genebank.

Rank	Company	Revenue		
		CY 2013 (\$M)	CY 2012 (\$M)	Change over 2012
1	Sinopharm	25,886.8	20,767.1	25%
2	China National Accord Medicines Corporation	3,272.7	2,719.0	20%
3	Yunnan Baiyao Group	2,447.7	2,095.4	17%
4	North China Pharmaceutical	1,929.6	1,692.7	14%
5	CSPC Pharmaceutical Group	1,233.3	513.9	140%
6	Shenzhen Neptunus Bioengineer	1,237.8	973.7	27%
7	Sino Biopharmaceutical	1,227.3	1,032.1	19%
8	Sanjiu Medical & Pharmaceutical	1,203.4	1,052.9	14%
9	The United Laboratories International	948.1	870.4	9%
10	Livzon Pharmaceutical	708.8	596.8	19%
11	Huapont-Nutrichem	685.7	584.9	17%
12	Shandong Dong-E E-Jiao	622.3	463.7	34%
13	CK Life Sciences	616.1	563.3	9%
14	Apeloa Company	603.4	526.1	15%
15	Shandong Xinhua Pharmaceutical	483.8	446.1	8%
16	Lijun International Pharmaceutical	432.5	301.3	44%
17	Jinling Pharmaceutical	403.1	349.8	15%
18	Shenzhen Salubris Pharmaceuticals	361.0	276.8	30%
19	Zhejiang Xianju Pharmaceutical	346.4	297.4	16%
20	China Grand Pharmaceutical and Healthcare	329.5	255.2	29%

* Revenue of listed companies only